Dr. Gary Lewis, MD
Claim this profileUniversity of Arkansas for Medical Sciences
Studies Cancer
Studies Squamous Cell Carcinoma
6 reported clinical trials
14 drugs studied
Area of expertise
1Cancer
p16 positive
Stage IV
p16 negative
2Squamous Cell Carcinoma
p16 positive
Stage IV
p16 negative
Affiliated Hospitals
Clinical Trials Gary Lewis, MD is currently running
High-Dose vs Low-Dose Cisplatin with Radiation
for Head and Neck Cancer
This phase II/III trial compares the effect of the combination of high-dose cisplatin every three weeks and radiation therapy versus low-dose cisplatin weekly and radiation therapy for the treatment of patients with locoregionally advanced head and neck cancer. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. This study is being done to find out if low-dose cisplatin given weekly together with radiation therapy is the same or better than high-dose cisplatin given every 3 weeks together with radiation therapy in treating patients with head and neck cancer.
Recruiting1 award Phase 2 & 335 criteria
DaRT Seeds
for Skin Cancer
This is a multi-center clinical study enrolling up to 86 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral administration of DaRT - Diffusing Alpha-Emitters Radiation Therapy, as well as to assess the Duration of Response (DOR) 6 months from initial response. Secondary objectives are to assess the safety of DaRT, and to assess the progression free survival (PFS), overall survival (OS), Overall Duration of Response (O-DOR), local control and quality of life (QOL) for patients treated with DaRT.
Recruiting1 award N/A24 criteria
More about Gary Lewis, MD
Clinical Trial Related2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Gary Lewis, MD has experience with
- Cisplatin
- DaRT224
- Atezolizumab
- Bevacizumab
- Cetuximab
- Docetaxel
Breakdown of trials Gary Lewis, MD has run
Cancer
Squamous Cell Carcinoma
Oropharyngeal Cancer
Laryngeal Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gary Lewis, MD specialize in?
Gary Lewis, MD focuses on Cancer and Squamous Cell Carcinoma. In particular, much of their work with Cancer has involved p16 positive patients, or patients who are Stage IV.
Is Gary Lewis, MD currently recruiting for clinical trials?
Yes, Gary Lewis, MD is currently recruiting for 3 clinical trials in Little Rock Arkansas. If you're interested in participating, you should apply.
Are there any treatments that Gary Lewis, MD has studied deeply?
Yes, Gary Lewis, MD has studied treatments such as Cisplatin, DaRT224, Atezolizumab.
What is the best way to schedule an appointment with Gary Lewis, MD?
Apply for one of the trials that Gary Lewis, MD is conducting.
What is the office address of Gary Lewis, MD?
The office of Gary Lewis, MD is located at: University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 United States. This is the address for their practice at the University of Arkansas for Medical Sciences.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.